{
    "clinical_study": {
        "@rank": "25085", 
        "arm_group": [
            {
                "arm_group_label": "Bupivacaine", 
                "arm_group_type": "Active Comparator", 
                "description": "Bupivicaine .03ml to each nare"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "normal saline .03 ml to each nare"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the efficacy of shenopalatine nerve block\n      utilizing the Tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the\n      duration of the analgesia."
        }, 
        "brief_title": "Sphenopalatine Nerve Block for Headache TX 360", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Headache", 
            "Migraine"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Headache", 
                "Migraine Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  are 18 - 65 years of age\n\n          -  present to ED triage with chief complaint of crescendo-onset anterior/frontal\n             headache (affecting frontal, temporal, orbital, maxillary, and mandible region)\n\n          -  have a normal neurological exams\n\n        Exclusion Criteria:\n\n          -  are less than 18 years old or greater than 65\n\n          -  have any focal neurological dysfunction signs or symptoms\n\n          -  have a posterior/occipital/cervicogenic source predominance of headache\n\n          -  are febrile (oral temperature 37.7 C or 100 F) or signs of acute or chronic\n             sinusitis, such as congestion, has been present more than 10 days, there is a high\n             fever, the nasal mucus is an abnormal color, or complains of face pain or headaches\n\n          -  have self treated with pain medication or anti-emetic 4 hours prior to arrival\n\n          -  have a history of peripheral vascular disease, cancer, or HIV infection\n\n          -  are known to be pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939314", 
            "org_study_id": "TX 360 HA -Schaffer", 
            "secondary_id": "Tian Medical Inc."
        }, 
        "intervention": [
            {
                "arm_group_label": "Bupivacaine", 
                "description": "intervention", 
                "intervention_name": "Bupivacaine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Normal Saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bupivacaine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Headache", 
            "Migraine"
        ], 
        "lastchanged_date": "September 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46202"
                }, 
                "name": "Indiana University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized, Double-Blind Study Comparing the Efficacy of Sphenopalatine Nerve Block by Localized Mucosal Application of an Anesthetic vs Placebo for the Emergency Department Management", 
        "overall_official": {
            "affiliation": "Indiana University", 
            "last_name": "Jason T Schaffer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subsequent pain scores using the visual, horizontal, analog scales and pain relief score using a categorical scale will be performed at 5 minutes and 15 minutes after the dosing of treatment drug or placebo.", 
            "measure": "Pain Score", 
            "safety_issue": "No", 
            "time_frame": "up to 15 minutes from dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939314"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Indiana University", 
            "investigator_full_name": "Terry Barclay", 
            "investigator_title": "Research Project Manager", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Following treatment, patients will  be asked to assess the amount of pain relief they experienced using a categorical score at 5 and 15 minutes for a total of two evaluations.", 
            "measure": "Pain Relief", 
            "safety_issue": "No", 
            "time_frame": "up to 15 mins from dose"
        }, 
        "source": "Indiana University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Indiana University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}